weight-loss drugs
Scope
Date
~
-
Bio & Pharma
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Apr 28, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Apr 17, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Apr 10, 2025 (Gmt+09:00)
-
Entertainment
Kakao Entertainment sheds loss-making units, revives IPO prospects
Kakao Entertainment Corp. has been divesting unprofitable music labels and digital content platforms, which it has gobbled up over the past few year...
Apr 07, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
Mar 25, 2025 (Gmt+09:00)
-
Bio & Pharma
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Mar 18, 2025 (Gmt+09:00)
-
Leadership & Management
Samsung in 'do or die' situation'; Lee sounds crisis alarm
Samsung Electronics Co. Chairman Lee Jae-yong has warned the company's executives that the South Korean tech giant has lost its characteristic "rele...
Mar 17, 2025 (Gmt+09:00)
-
Stocks
China stock funds outperform US funds in South Korea
Chinese stocks are attracting South Korean investors looking beyond Wall Street amid the downturn in US Big Tech stocks.South Korea’s equity f...
Mar 12, 2025 (Gmt+09:00)
-
Pension funds
South Korea’s pension fund NPS risks massive loss from Homeplus fiasco
South Korea’s National Pension Service (NPS), the nation’s biggest institutional investor, could lose more than 1 trillion won ($692 mil...
Mar 07, 2025 (Gmt+09:00)
-
Foreign exchange
South Korea’s forex reserves dip to nearly 5-year low in February
South Korea’s foreign exchange reserves diminished to the lowest level in nearly five years last month, largely due to the expanded forex swap...
Mar 06, 2025 (Gmt+09:00)
-
Bio & Pharma
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Feb 27, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Feb 25, 2025 (Gmt+09:00)
-
Corporate bonds
One-third of Korean petrochem bonds incur valuation losses
South Korean institutional investors, including banks, insurers and securities companies, have yet to fully benefit from recent declines in bond yie...
Feb 24, 2025 (Gmt+09:00)
-
Earnings
SK Hynix surpasses Samsung with record-high profit in Q4
SK Hynix Inc., the top supplier of high-bandwidth memory (HBM) chips to Nvidia Corp., on Thursday reported its highest-ever quarterly profit of 8.08...
Jan 23, 2025 (Gmt+09:00)
-
Bio & Pharma
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Jan 17, 2025 (Gmt+09:00)
-
IPOs
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
Jan 16, 2025 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
Jan 15, 2025 (Gmt+09:00)
-
Earnings
LG Energy logs 1st quarterly loss in over 3 years, outlook remains gloomy
LG Energy Solution Ltd. reported its first quarterly loss in more than three years on Thursday, adding to concerns that the world’s third-larg...
Jan 09, 2025 (Gmt+09:00)
-
Bio & Pharma
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Dec 31, 2024 (Gmt+09:00)
-
Bio & Pharma
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
Dec 12, 2024 (Gmt+09:00)
-
Economy
Korean economic policy chiefs play down martial law impact
South Korea’s Finance Minister Choi Sang-mok said on Friday that President Yoon Suk Yeol’s failed martial law attempt will have a very l...
Dec 06, 2024 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
Dec 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Nov 25, 2024 (Gmt+09:00)
-
Bio & Pharma
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
Nov 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Nov 20, 2024 (Gmt+09:00)
-
Retail
Korean duty-free shops post Q3 losses; no signs of recovery
The four major duty-free shop operators in South Korea on Thursday posted operating losses in the third quarter, marking the first quarter in almo...
Nov 14, 2024 (Gmt+09:00)
-
Automobiles
Hyundai Mobis develops leaf spring with advanced materials
South Korea's Hyundai Mobis, the world’s fifth-largest auto parts supplier, said on Monday that it developed a leaf spring using lightweight p...
Nov 11, 2024 (Gmt+09:00)
-
Corporate restructuring
Fila sportswear brand downsizes loss-making US business
South Korean-owned sportswear brand Fila said on Tuesday it scaled back its loss-making US business to improve earnings through a restructuring in N...
Nov 06, 2024 (Gmt+09:00)
-
Food & Beverage
Loss-making Pizza Hut Korea files for rehabilitation
Money-losing Pizza Hut Korea Ltd., the Korean master franchisee of the giant US pizza franchisor, has filed for corporate rehabilitation in Seoul in...
Nov 05, 2024 (Gmt+09:00)
-
Corporate restructuring
SK Innovation-SK E&S merger creates Asia’s No. 1 energy supplier
SK Group on Friday launched the merged entity between SK Innovation Co. and liquefied natural gas supplier SK E&S Co., a key step in the energy-...
Nov 01, 2024 (Gmt+09:00)
Latest News
- 1 Woori Financial wins approval for Tongyang, ABL Life acquisition
- 2 BMW surpasses Mercedes in Korean sales amid imported vehicle market shake-up
- 3 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 4 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 5 Trump Jr. meets Korean business chiefs in back-to-back sessions